7D30

Structure of sybody MR17-SR31 fusion in complex with the SARS-CoV-2 S Receptor Binding domain (RBD)

7D30 の概要

• エントリーDOI: 10.2210/pdb7d30/pdb
• 分子名称: sybody fusion of MR17-SR31 with a GS linker, Spike protein S1, alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-3)][alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, ... (9 entities in total)
• 機能のキーワード: coronavirus, covid-19, nanobody, neutralizing antibody, receptor binding protein, sars-cov-2, s protein, synthetic antibody, vhh., protein binding
• 由来する生物種: synthetic construct; 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 60133.98

構造登録者

Li, T.,Yao, H.,Cai, H.,Qin, W.,Li, D. (登録日: 2020-09-17, 公開日: 2021-02-17, 最終更新日: 2023-11-29)

• 主引用文献: Yao, H.,Cai, H.,Li, T.,Zhou, B.,Qin, W.,Lavillette, D.,Li, D.; A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.; Plos Pathog., 17:e1009328-e1009328, 2021; PubMed: 33657135; DOI: 10.1371/journal.ppat.1009328

実験手法

X-RAY DIFFRACTION (2.1 Å)